Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today.
| Director Nominee | Outcome | % For | % Withheld
|
| Roderick Flower | Elected | 90.77% | 9.23% |
| Robert E. Hoffman | Elected | 81.08% | 18.92% |
| Amal Khouri | Elected | 90.74% | 9.26% |
| Dan Legault | Elected | 90.62% | 9.38% |
| Walt Macnee | Elected | 90.81% | 9.19% |
| Jennifer McNealey | Elected | 80.31% | 19.69% |
| Yung Wu | Elected | 90.80% | 9.20% |
Voting results on all matters voted on at the Meeting have been filed on SEDAR.
About Antibe Therapeutics Inc.
Antibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation therapies to target inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today’s NSAIDs for acute pain. Antibe’s second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230908760977/en/
Contacts
Antibe Therapeutics Inc.
Christina Cameron
VP Investor Relations
+1 416-577-1443
christina@antibethera.com
Source: Antibe Therapeutics Inc.
View this news release online at:
http://www.businesswire.com/news/home/20230908760977/en
